The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The Symphony pharmacokinetic substudy

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2269-2276

  Grinyó, Josep M ^a   Ekberg, Henrik ^b   Mamelok, Richard D ^c   Oppenheimer, Federico ^d   Sánchez Plumed, Jaime ^e   Gentil, Miguel Angel ^f   Hernandez, Domingo ^g   Kuypers, Dirk R ^h   Brunet, Mercé ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b LUND UNIVERSITY   (Sweden)

^c Mamelok Consulting   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e HU la Fe   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Mycophenolate mofetil; Mycophenolic acid; Mycophenolic acid glucuronide; Pharmacokinetics; Renal transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG GLUCURONIDATION; DRUG METABOLISM; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 67651115805     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp162     Document Type: Article

References (34)

1. Gonzalez-Molina MG, Seron D, Del Moral RG et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. Transplantation 2004; 77: 215-220
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58
3. Shaw LM, Rosemarie M, Nowak I et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998; 38: 268-275
4. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266
5. van Hest RM, Mathot RA, Pescovitz MD et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871-880
6. Kuypers DRJ, Naesens M, Vermeire S et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005; 78: 351-361
7. Naesens M, Kuypers DRJ, Verbeke K et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-1084
8. Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5: 225-232
9. Kuriata-Kordek M, Boratynska M, Falkiewicz K et al. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. Transplant Proc 2003; 35: 2369-2371
10. Buchler M, Lebranchu Y, Beneton M et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine treatment. Clin Pharmacol Ther 2005; 78: 34-42
11. Cattaneo D, Merlini S, Zenoni S et al. Influence of comedication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937-2944
12. Picard N, Premaud A, Rousseau A et al. Comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 2006; 62: 477-484
13. Naito T, Shinno K, Maeda T et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull 2006; 29: 275-280
14. El Haggan W, Ficheux M, Debruyne D et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. Transplant Proc 2005; 37: 864-866
15. Hesselink DA, Van Hest RM, Mathot RAA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multi-drug resistance-associated protein 2. Am J Transplant 2005; 5: 987-994
16. Kobayashi M, Saitoh H, Kobayashi M et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004; 309: 1029-1035
17. Pescovitz MD, Bumgardner G, Gaston RS et al. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 2003; 17: 511-517
18. Cattaneo D, Perico N, Gaspari F et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060-1067
19. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
20. Brunet M, Cirera I, Martorell J et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006; 81: 541-546
21. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011-1017
22. Brunet M, Campistol JM, Diekmann F et al. T cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther 2007; 11: 247-256
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
24. Ekberg H, Halloran P. Reduced exposure to calcineurin inhibitors in renal transplantation. NEnglJMed 2008; 358: 2518-2520
25. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000; 14: 100-104
26. Pescovitz MD, Vincenti F, Hart M et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007; 64: 758-771
27. Kuypers DRJ, Vanrenterghem Y, Squifflet JP et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609-622
28. Borrows R, Chusney G, James A et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit 2005; 27: 442-450
29. van Gelder T, Klupp J, Barten MJ et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128
30. Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999; 39: 715-720
31. Naesens M, de Loor H, Vanrenterghem Y et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362-373
32. Atcheson BA, Taylor PJ, Kirckpatrick CM. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004; 26: 284-286
33. Weiland E, Shipkova M, Schellhaas U et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107-113
34. Heller T, van Gelder T, Budde K et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007; 7: 1822-1831